CJ Bio Expands Probiotic Portfolio, Kaneka Targets Reproductive Health, Sirio Sees APAC Gummy Growth

Seoul-based CJ Bio has diversified its probiotic ingredient offering by introducing two new _Bifidobacterium_ strains: _Bifidobacterium bifidum_ PRO G814 and _Bifidobacterium animalis subsp. lactis_ PRO G952. These strains, unveiled under the BiomeNrich brand at Vitafoods Europe, mark the company's first foray beyond its established _Lactobacillus_ portfolio. This expansion provides manufacturers with increased flexibility in formulating products targeting specific gut health outcomes, potentially intensifying competition in the probiotic raw material market.

Separately, Kaneka Corporation is addressing a significant gap in consumer understanding regarding reproductive health and mitochondrial function. The company highlights that while age is a recognised factor in declining reproductive health, the role of cellular mitochondria is often overlooked. Kaneka, a key supplier of Ubiquinol – a mitochondrial co-factor and antioxidant – aims to educate the market on its ingredient's support for mitochondrial activities, including fertility. This strategic positioning could drive demand for Ubiquinol in a nascent but high-value segment.

Contract development and manufacturing organisation Sirio Pharma has identified substantial growth opportunities within the Asia-Pacific gummy nutraceutical sector. The China-based firm pinpoints kids' nutrition in Indonesia, 'beauty-from-within' applications in Thailand, and sports nutrition in both Australia and Singapore as particularly promising sub-segments. Sirio's analysis underscores the region's readiness for innovative gummy formats, suggesting brands should prioritise these markets for new product launches or reformulations. This insight is critical for brands seeking to optimise their APAC market entry or expansion strategies.

Furthermore, Australia-based NiHTEK has developed NiHPRO, a plant-based hydrolysed protein isolate designed to mimic whey's mouthfeel, digestibility, and amino acid profile, without dairy. Comprising pea protein, rice protein, and essential amino acids, NiHPRO targets sports nutrition and the growing market of GLP-1 users seeking high-protein, dairy-free alternatives. This innovation offers manufacturers a novel protein source that addresses common consumer dietary preferences and intolerances, potentially expanding product appeal. The Healthy Grain (THG) has also broadened its reach in Japan and Taiwan for its Super Barley™ BARLEYMAX through a strategic partnership with Itochu Corporation, targeting fibre fortification in RTE meals, bakery, and granolas, indicating strong demand for functional food ingredients in the region.

What this means for Asia-Pacific

Brand owners and manufacturers in Asia-Pacific must assess the commercial implications of these supplier developments. CJ Bio's new _Bifidobacterium_ strains provide more diverse ingredient options for targeted probiotic formulations, potentially influencing ingredient procurement and pricing. Kaneka's focus on reproductive health with Ubiquinol creates a niche market opportunity; early adoption by brands could secure first-mover advantage, necessitating R&D investment and targeted consumer education. Sirio Pharma's identification of high-growth gummy segments in Indonesia, Thailand, Australia, and Singapore offers clear product development blueprints. Brands should evaluate current product portfolios against these opportunities, potentially initiating new SKU development or reformulation projects within 6-9 months to capitalise on identified market demand.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.